Drug profile · INN
butabarbital sodium
SODIUM BUTABARBITAL
butabarbital sodium (SODIUM BUTABARBITAL) is a gaba-a receptor; anion channel positive allosteric modulator. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — butabarbital sodium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
butabarbital sodium (SODIUM BUTABARBITAL) is a gaba-a receptor; anion channel positive allosteric modulator. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
GABA-A receptor; anion channel positive allosteric modulator
Primary target: GABA-A receptor; anion channel
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is butabarbital sodium?
butabarbital sodium (SODIUM BUTABARBITAL) is a gaba-a receptor; anion channel positive allosteric modulator. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for butabarbital sodium?
SODIUM BUTABARBITAL is a marketed brand name for butabarbital sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of butabarbital sodium?
butabarbital sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.